BTH to develop new technologies to improve quality of life for elderly people with mild dementia

NewsGuard 100/100 Score

Blekinge Institute of Technology in Sweden will receive 10 million SEK to develop new technologies that will increase the quality of life for elderly people with mild dementia. The technology, IT support via e-readers, will also facilitate for the relatives.

It is from Horizon 2020, the EU Framework Programme for Research and Innovation, that the project Medical Intelligence for Assistive Management Interface - Mild Dementia received the funds. The project will last for four years.

In the project, new specially adapted technology that can help elderly people suffering from mild dementia will be developed. This may involve, for example reminders so they do not forget to take their medication or an appointment. In addition to raising the quality of life for these elderly people the new technologies will make it easier for relatives and healthcare professionals.

Today, up to 9 percent of the population over 60 years suffer from mild dementia, so there are a great number of people who will have use of the new technology.

The first step is to develop a customized technology that is user friendly. Then the technology will be tested on 2,000 people in Europe. The new technology is expected to be ready for operation in 2020.

The work will be conducted within the research environments sustainable active aging and health and technology at BTH. Responsible for the project is Johan Berglund, professor of public health sciences. The senior project SNAC-Blekinge, which enabled this EU project, has been underway at BTH since 2000.

- With this technology, we hope to support and develop nursing care, increase the elderly persons and their family members' quality of life while also reducing health care costs, says Professor Johan Berglund.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Single-dose genetic medicine halts the progression of ALS and frontotemporal dementia in mice